WebApr 6, 2024 · Key Points. Question Does first-line nivolumab plus ipilimumab provide clinical benefit vs nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)?. Findings In this randomized clinical trial of 425 adults with platinum-refractory or platinum-eligible R/M SCCHN, the primary end point of objective … Web1. Paz-Ares LG, Ciuleanu T-E, Lee J-S, et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. Presented at: 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2024. Abstract 9016.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab …
WebNov 21, 2024 · Nivolumab plus Ipilimumab in Non–Small-Cell Lung Cancer. To the Editor: Although more than 10% of the patients in the CheckMate 227 trial conducted by Hellmann et al. (Nov. 21 issue) 1 had never ... WebApr 19, 2024 · The CheckMate 227 is an open-label phase III trial evaluating multiple hypotheses regarding the efficacy of nivolumab or nivolumab-based regimens as first-line treatment in biomarker-selected populations of patients with advanced NSCLC. On the basis of the emerging data related to TMB, the CheckMate 227 study protocol was amended … does lung cancer have a genetic component
Nivolumab plus Ipilimumab in Non–Small-Cell Lung Cancer
WebFirst-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial J Thorac Oncol. 2024 … CheckMate 227 is the first phase III study to report 5-year clinical outcomes with a first-line immunotherapy combination for mNSCLC. Nivolumab plus ipilimumab conferred long-term clinical benefit extending beyond treatment discontinuation, regardless of PD-L1 expression. WebEfficacy was investigated in CHECKMATE-227 (NCT02477826), a randomized, open-label, multi-part trial in patients with metastatic or recurrent NSCLC and no prior anticancer … facebook 787